Professor Moein Moghimi is a globally recognized authority in nanomedicine, nanoparticle design, and targeted drug delivery. With decades of pioneering research in pharmaceutical nanoscience, nanomedicine, and nanosafety, he has made significant contributions to the development of advanced nanotherapeutics and their safe clinical translation. His work has been widely published, and he has played a key role in shaping the field through both research and advisory roles.

​

Since August 2017, Professor Moghimi has served as Professor of Pharmaceutics at the School of Pharmacy and Research Professor at the Institute of Cellular Medicine at Newcastle University, UK. He also holds an adjunct professorship at the Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Denver Medical Center, USA. Previously, he was Professor and Chair in Pharmaceutics at Durham University’s School of Medicine, Pharmacy, and Health (UK).

​

Professor Moghimi has held distinguished research and academic positions worldwide, including as a Full Affiliate Member/Professor at the Department of Translational Imaging, Houston Methodist Research Institute (USA), and Visiting Professor at Università Degli Studi Di Padova (Italy) in 2015. From 2008 to 2016, he was Professor of Nanomedicine at the University of Copenhagen (Denmark), where he also founded and directed the Centre for Pharmaceutical Nanotechnology and Nanotoxicology, Denmark’s first interdisciplinary nanomedicine research center. His prior roles include honorary professorships at Shantou University (China) and leadership positions at the University of Brighton and the University of Nottingham.

​

Beyond academia, Professor Moghimi has served as an expert advisor and consultant to over 50 pharmaceutical, biotechnology, healthcare, and investment organizations worldwide. His expertise is frequently sought by governmental bodies, research councils, and private institutions, having been an assessor and evaluator for over 50 establishments across 25 countries.

​

His groundbreaking research spans nanomedicine, pharmaceutical nanoscience, and nanosafety, with a strong focus on nanoparticle engineering for site-specific drug delivery and imaging, splenotropic and lymphotropic nanocarriers, phagocyte-resistant nanoparticles, and cerebral endothelial-targeting nanosystems. He has also provided key mechanistic insights into nanomaterial-mediated infusion reactions and cell death pathways.

​

Professor Moghimi’s contributions have earned him numerous international accolades. As principal investigator, he has secured over €30 million in competitive research funding and played a vital role in large-scale European Commission FP-7 programs on translational nanomedicine, including The NAD Project (Alzheimer’s Disease) and CosmoPHOS NANO (Atherosclerosis). The NAD Project was highlighted as a Horizon 2020 success story, received the Best Project Award in Industrial Technologies, and was personally endorsed by the EU President.

​

To date, Professor Moghimi has published over 300 peer-reviewed journal articles, contributed to multiple patent applications, and edited leading scientific journal issues. He has delivered over 300 invited lectures and keynote addresses across more than 30 countries.

​

Professor Moghimi earned his PhD in Biochemistry from Imperial College London (Charing Cross and Westminster Medical School) and completed a prestigious SERC-funded postdoctoral fellowship in Advanced Drug Delivery at the University of Nottingham.

 

For more details visit his Wikipedia page

​

More about Professor Moein Moghimi

​

​